Skip to content

On the status of glucose intolerance and islet dysfunction in primary breast cancer patients at initial diagnosis, during chemotherapy and after systemic treatment

On the status of glucose intolerance and islet dysfunction in primary breast cancer patients at initial diagnosis, during chemotherapy and after systemic treatment

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ECS-14004507
Enrollment
Unknown
Registered
2014-04-12
Start date
2014-04-16
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Initial diagnosis group:non
Chemotherapy group:non
Post-systematic treatment group:non

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Initial diagnosis group: 1. initially diagnosed as primary breast cancer through pathology in our hospital or initially diagnosed at other hospital then verified by pathologist of our hospital; 2. Male or female 18-75 years old. Chemotherapy group: 1. Having been diagnosed as breast cancer through pathology; 2. During systematic chemotherapy of breast cancer(before the 5th or 6th cycle of chemotherapy); 3. Male or female 18-75 years old. Post-systematic treatment group: 1. Breast cancer patients with a history of standard systematic therapy more than 3 months in our hospital; 2. Male or female 18-75 years old.

Exclusion criteria

Exclusion criteria: 1. Accompanied with trauma, infection, recent surgery or pregnancy breast cancer; 2. Accompanied with other endocrine diseases, such as: acromegaly, Cushing disease, glucagonoma, pheochromocytoma, hyperthyroidism, somatostatinoma, aldosteronoma, etc.; 3. Taking medicine affecting blood glucose but cannot be stopped, such as: glucocorticoid, thyroid hormone, diazoxide, adrenergic agonist, thiazine diuretic, dilantin, etc.; 4. A patient cannot be included in chemotherapy group repeatedly.

Design outcomes

Primary

MeasureTime frame
OGTT;C peptide releasing test;Insulin releasing test;

Countries

China

Contacts

Public ContactKong Lingquan

The First Affiliated Hospital of Chongqing Medical University

huihuikp@163.com+86 13101380893

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026